OrthoTrophix

OrthoTrophix is an emerging biopharmaceutical company focused on the development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone, cartilage, and teeth. OrthoTrophix’s primary focus is on the regeneration and repair of cartilage in the knee and other joints. The company's leading therapeutic compound, TPX-100, has demonstrated favorable safety in Phase 2 clinical studies, along with statistically significant and clinically meaningful improvements in knee function and other parameters in subjects with knee osteoarthritis. Moreover, significant improvements in knee function were associated with notable enhancements in knee cartilage thickness and volume. Prior to initiating clinical research, TPX-100 had already demonstrated the ability to repair articular (hyaline) cartilage in experimental knee defects in a dynamic large animal model.